许多肿瘤组织同时表达EGFR及其配体,EGFR及其配体网络已经明确为肿瘤治疗的重要靶点。EGFR抑制剂以其高选择性和低毒性的优势在肿瘤临床治疗中令人瞩目。但EGFR表达并不是决定EGFR抑制剂疗效的唯一因素,肿 Many tumor tissues express EGFR and its ligands simultaneously. The network of EGFR and its ligand has been identified as an important target of tumor therapy. EGFR inhibitors attract people’s attention in the clinical treatment of tumors because of their high selectivity and low toxicity. However, EGFR expression is not the only factor that determines the efficacy of EGFR inhibitors